Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Brain Neoplasms 23Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 16Lung Neoplasms 11Neoplasm Metastasis 8Melanoma 6Breast Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Carcinoma, Renal Cell 4Small Cell Lung Carcinoma 3Meningioma 3Urinary Bladder Neoplasms 2Sarcoma 2Prostate Adenocarcinoma 2Neoplasms 2Kidney Neoplasms 2Head and Neck Neoplasms 2Glioblastoma 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Adenocarcinoma of Lung 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Diseases 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Stage II Prostate Adenocarcinoma AJCC v7 1

Interventions

luprolide acetate gel depot 1enzalutamide 1Triptorelin Pamoate 1Radiosurgery 1Leuprolide 1Goserelin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Castration-resistant Prostate Cancer Patients with Oligometastases × Radiosurgery × Clear all
NCT02685397 2024-12-04

PCS IX

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2/3 Active not recruiting
102 enrolled
Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡